Publication | Open Access

Phillyrin (KD-1) exerts anti-viral and anti-inflammatory activities against novel coronavirus (SARS-CoV-2) and human coronavirus 229E (HCoV-229E) by suppressing the nuclear factor kappa B (NF-κB) signaling pathway

InflammationAnti-inflammatoryNovel CoronavirusImmunologyPharmacologyChronic InflammationAntiviral Drug DevelopmentInnate ImmunityAnti-inflammatory ActivitiesAntiviral DrugMedicineCell SignalingHuman Coronavirus 229ECovid-19